Company news

Geron Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

November 3, 2026

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

October 28, 2026

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

October 21, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 19, 2026

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

October 12, 2026

Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

October 12, 2026

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 5, 2026

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 22, 2026

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 14, 2026

July 15, 2026

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

July 13, 2026

Geron Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

June 19, 2026

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 1, 2026

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

May 12, 2026

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 6, 2026

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

April 22, 2026

Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

April 12, 2026

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 5, 2026

Geron Announces Appointment of New Members to its Board of Directors

March 25, 2026

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 24, 2026

Geron Plans to Present at Upcoming Investor Conferences

February 22, 2026

Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 11, 2026

Geron Corporation Provides 2026 Financial Guidance

January 11, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 17, 2025

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

December 10, 2025

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

December 7, 2025

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 4, 2025

Geron Corporation to Present at Upcoming Investor Conferences

November 3, 2025

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

November 2, 2025

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 26, 2025

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

October 22, 2025

Geron Corporation Announces Executive Leadership Transitions and Appointments

October 12, 2025

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

August 26, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

August 19, 2025

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2025

Geron Appoints Harout Semerjian as President and Chief Executive Officer

August 6, 2025

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 5, 2025

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 27, 2025

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 27, 2025

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2025

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

March 30, 2025

Geron Corporation Announces Departure of Chief Executive Officer

March 10, 2025

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

March 10, 2025

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 25, 2025

Geron to Participate at Upcoming Investor Conferences in March 2025

February 20, 2025

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

February 2, 2025

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

December 12, 2024

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

December 9, 2024

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

December 9, 2024

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.